In light of the emerging role of miRNAs and their interactions with ABC transporters, future therapeutic strategies for overcoming doxorubicin resistance in CRC should prioritize a deeper exploration of these molecular mechanisms. The gene discussed is ABCG2; the disease is colorectal carcinoma.